Darolutamide with hormone therapy for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how well the drug darolutamide works when combined with hormone therapy, with or without chemotherapy, for men whose prostate cancer has spread. It aims to see how effective this treatment is in everyday medical practice, not just in a research lab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older (or the legal adult age in your country, if that is older).
- You have been diagnosed with prostate cancer that has spread to other parts of the body (metastatic), and it is confirmed by biopsy or cell sample.
- You have not had hormone therapy for the cancer that has spread before starting this treatment.
- You have not taken certain other prostate cancer drugs (like enzalutamide, apalutamide, or abiraterone) recently, except abiraterone if it was stopped at least 24 months before your cancer spread was found.
- You and your doctor have already decided to start treatment with darolutamide (with or without chemotherapy) before you join the study.
- You are expected to live at least 3 more months.
- You have not already started darolutamide for more than 7 days before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well darolutamide and similar drugs work for men whose prostate cancer has just spread to other parts of the body. It aims to understand real-world outcomes in urology clinics.
This study tests a triple treatment (darolutamide, hormone therapy, and chemotherapy) for men whose prostate cancer has spread and still responds to hormone therapy. The goal is to see if this combination works better than standard care in controlling the cancer and improving outcomes.
This study tests a drug called darolutamide combined with standard hormone therapy for men whose prostate cancer has spread to other parts of the body and still responds to hormone treatment. The goal is to see if this combination helps control the cancer better than hormone therapy alone.
This trial tests a combination of two drugs (darolutamide plus hormone therapy) along with a low dose of chemotherapy (docetaxel) for men whose prostate cancer has spread to other parts of the body. It aims to see if this combined approach is safe and effective.
This study looks at how well a drug called darolutamide (a type of hormone therapy) works in everyday medical practice for men with advanced prostate cancer that has spread. It is for men who are already starting this treatment with their doctor and will help doctors understand how it works in real life.
This study watches how well a drug called darolutamide works when combined with hormone therapy for men with prostate cancer that has returned after previous treatment. The goal is to understand if this combination helps prevent cancer spread and is safe to use.
Hear when a new Metastatic Hormone-Sensitive Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.